These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 29988148)

  • 21. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-associated Fibroblast-promoted LncRNA
    Zhang H; Hua Y; Jiang Z; Yue J; Shi M; Zhen X; Zhang X; Yang L; Zhou R; Wu S
    Clin Cancer Res; 2019 Mar; 25(6):1989-2000. PubMed ID: 30463848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
    Zhou B; Sun C; Li N; Shan W; Lu H; Guo L; Guo E; Xia M; Weng D; Meng L; Hu J; Ma D; Chen G
    Int J Oncol; 2016 May; 48(5):2087-97. PubMed ID: 26983899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.
    Li DJ; Shi M; Wang Z
    Thorac Cancer; 2016 Sep; 7(5):570-580. PubMed ID: 27766776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling.
    Cui Y; Zhang S; Hu X; Gao F
    Bioengineered; 2022 May; 13(5):12462-12474. PubMed ID: 35587143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF‑α‑mediated upregulation of SOD‑2 contributes to cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma.
    Zuo J; Zhao M; Liu B; Han X; Li Y; Wang W; Zhang Q; Lv P; Xing L; Shen H; Zhang X
    Oncol Rep; 2019 Oct; 42(4):1497-1506. PubMed ID: 31364751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
    Shi JJ; Xing H; Wang YX; Zhang X; Zhan QM; Geng MY; Ding J; Meng LH
    Cancer Lett; 2019 Sep; 459():145-155. PubMed ID: 31173854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.
    Liu T; Guan F; Wang Y; Zhang Z; Li Y; Cui Y; Li Z; Liu H; Zhang Y; Wang Y; Ma S
    Toxicol Appl Pharmacol; 2020 May; 395():114971. PubMed ID: 32217144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging role of cancer-associated fibroblasts in esophageal squamous cell carcinoma.
    Li W; Xu T; Jin H; Li M; Jia Q
    Pathol Res Pract; 2024 Jan; 253():155002. PubMed ID: 38056131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting MFGE8 secreted by cancer-associated fibroblasts blocks angiogenesis and metastasis in esophageal squamous cell carcinoma.
    Liu B; Zhang B; Qi J; Zhou H; Tan L; Huang J; Huang J; Fang X; Gong L; Luo J; Liu S; Fu L; Ling F; Ma S; Lai-Wan Kwong D; Wang X; Guan XY
    Proc Natl Acad Sci U S A; 2023 Oct; 120(42):e2307914120. PubMed ID: 37816055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors.
    Chan JSK; Sng MK; Teo ZQ; Chong HC; Twang JS; Tan NS
    Oncogene; 2018 Jan; 37(2):160-173. PubMed ID: 28892046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
    Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
    Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer-associated fibroblasts secrete hypoxia-induced serglycin to promote head and neck squamous cell carcinoma tumor cell growth in vitro and in vivo by activating the Wnt/β-catenin pathway.
    Xie J; Qi X; Wang Y; Yin X; Xu W; Han S; Cai Y; Han W
    Cell Oncol (Dordr); 2021 Jun; 44(3):661-671. PubMed ID: 33651283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.
    Zhao J; Wu K; Yang Y; Liu D; Zhang C; Li X
    Bioorg Chem; 2024 Jun; 147():107384. PubMed ID: 38643568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis.
    Yu X; Li W; Xia Z; Xie L; Ma X; Liang Q; Liu L; Wang J; Zhou X; Yang Y; Liu H
    BMC Cancer; 2017 Jun; 17(1):449. PubMed ID: 28659182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity to Cisplatin in Head and Neck Cancer Cells Is Significantly Affected by Patient-Derived Cancer-Associated Fibroblasts.
    Peltanova B; Liskova M; Gumulec J; Raudenska M; Polanska HH; Vaculovic T; Kalfert D; Grega M; Plzak J; Betka J; Masarik M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer-associated fibroblasts confer cisplatin resistance of tongue cancer via autophagy activation.
    Liao JK; Zhou B; Zhuang XM; Zhuang PL; Zhang DM; Chen WL
    Biomed Pharmacother; 2018 Jan; 97():1341-1348. PubMed ID: 29156523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer.
    Sawayama H; Ogata Y; Ishimoto T; Mima K; Hiyoshi Y; Iwatsuki M; Baba Y; Miyamoto Y; Yoshida N; Baba H
    Cancer Sci; 2019 May; 110(5):1705-1714. PubMed ID: 30861255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.
    Tao L; Huang G; Wang R; Pan Y; He Z; Chu X; Song H; Chen L
    Sci Rep; 2016 Dec; 6():38408. PubMed ID: 27922075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.